Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.0342771982116245 -0.0461997019374069 -0.0214605067064085 -0.0250372578241431
Stock impact report

BRIEF-Hemispherx Provides An Update To Stockholders Highlighting Cancer Focus [Reuters]

HEMISPHERX BIOPHARMA (HEB) 
NASDAQ:AMEX Investor Relations: hemispherx.net/mobile/investor-relations.php
Company Research Source: Reuters
BRIEF-Hemispherx Provides An Update To Stockholders Highlighting Cancer Focus | Reuters Reuters Staff 1 Min Read May 2 (Reuters) - Hemispherx Biopharma Inc: * HEMISPHERX PROVIDES AN UPDATE TO STOCKHOLDERS HIGHLIGHTING CANCER FOCUS AND $10 MILLION BOOKED SINCE START OF YEAR WILL SUPPORT INCREASED PRODUCTION OF AMPLIGEN FOR IMMUNO-ONCOLOGY CLINICAL TRIALS Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. Show less Read more
Impact Snapshot
Event Time:
HEB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HEB alerts
Opt-in for
HEB alerts

from News Quantified
Opt-in for
HEB alerts

from News Quantified